Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4113-4122

  Mohamed, Mohamed F ^a   Hamed, Maha I ^a   Panitch, Alyssa ^b   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLARGININE; ARGINYLARGINYLISOLEUCYLLYSYLALANINE; L 9043; LINEZOLID; LYSOSTAPHIN; MAGNESIUM CHLORIDE; N 5764; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; SODIUM CHLORIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIMICROBIAL CATIONIC PEPTIDE; RECOMBINANT PROTEIN;

ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; LINEZOLID RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; HEMOLYSIS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELA CELLS; HEMOLYSIS; HUMANS; LYSOSTAPHIN; MAGNESIUM CHLORIDE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RECOMBINANT PROTEINS; SODIUM CHLORIDE; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANCE;

EID: 84903138381     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02578-14     Document Type: Article

References (44)

1. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. 2003. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984. http://dx.doi.org/10.1001/ jama.290.22.2976. (Pubitemid 37505530)
2. Tsuji BT, Rybak MJ, Cheung CM, Amjad M, Kaatz GW. 2007. Com-munity- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn. Microbiol. Infect. Dis. 58:41-47. http://dx.doi.org/10.1016/j. diagmicrobio.2006.10.021. (Pubitemid 46694261)
3. Stryjewski ME, Chambers HF. 2008. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl 5):S368-S377. http://dx.doi.org/10.1086/533593. (Pubitemid 351717324)
4. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl 5):S344-S349. http://dx.doi.org/10.1086/533590. (Pubitemid 351717321)
5. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641. http://dx.doi.org/10. 1038/nrmicro2200.
6. Boman HG. 1995. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 13:61-92. http://dx.doi.org/10.1146/annurev.iy.13.040195. 000425.
7. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a. (Pubitemid 34100944)
8. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. http://dx.doi.org/10.1038/nbt1267. (Pubitemid 44967479)
9. Silva ON, Mulder KC, Barbosa AE, Otero-Gonzalez AJ, Lopez-Abarrategui C, Rezende TM, Dias SC, Franco OL. 2011. Exploring the pharmacological potential of promiscuous host-defense peptides: from natural screenings to biotechnological applications. Front. Microbiol. 2:232. http://dx.doi.org/10.3389/fmicb.2011. 00232.
10. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42:2206-2214. (Pubitemid 28420351)
11. Chu HL, Yu HY, Yip BS, Chih YH, Liang CW, Cheng HT, Cheng JW. 2013. Boosting salt resistance of short antimicrobial peptides. Antimicrob. Agents Chemother. 57: 4050 - 4052. http://dx.doi.org/10.1128/AAC.00252-13.
12. Lopes LB, Flynn C, Komalavilas P, Panitch A, Brophy CM, Seal BL. 2009. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP kinase 2 inhibitor. Biochem. Biophys. Res. Commun. 382:535-539. http://dx.doi.org/10. 1016/j.bbrc.2009.03.056.
13. Lopes LB, Brophy CM, Flynn CR, Yi Z, Bowen BP, Smoke C, Seal B, Panitch A, Komalavilas P. 2010. A novel cell permeant peptide inhibitor of MAPKAP kinase II inhibits intimal hyperplasia in a human saphenous vein organ culture model. J. Vasc. Surg. 52:1596-1607. http://dx.doi.org/10.1016/j.jvs.2010.06.168.
14. Ward B, Seal BL, Brophy CM, Panitch A. 2009. Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J. Peptide Sci. 15:668-674. http://dx.doi.org/10.1002/psc.1168.
15. CLSI. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M-A7. CLSI, Wayne, PA.
16. Yan H, Hancock RE. 2001. Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob. Agents Chemother. 45: 1558-1560. http://dx.doi.org/10.1128/AAC.45.5.1558-1560.2001. (Pubitemid 32374135)
17. White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40:1914-1918. (Pubitemid 26277815)
18. Oliva B, Miller K, Caggiano N, O'Neill AJ, Cuny GD, Hoemann MZ, Hauske JR, Chopra I. 2003. Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob. Agents Chemother. 47:458-466. http://dx.doi.org/10.1128/AAC.47.2.458-466.2003. (Pubitemid 36158068)
19. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121. http://dx.doi.org/10.1128/AAC.49.8.3114-3121. 2005. (Pubitemid 41060548)
20. Yan J, Wang K, Dang W, Chen R, Xie J, Zhang B, Song J, Wang R. 2013. Two hits are better than one: membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin. Antimicrob. Agents Chemother. 57: 220-228. http://dx.doi.org/10.1128/ AAC.01619-12.
21. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. http://dx.doi.org/10.1016/0022-1759(83)90303-4. (Pubitemid 14203433)
22. Boman HG, Agerberth B, Boman A. 1993. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61:2978-2984. (Pubitemid 23182296)
23. Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244:253-257. http://dx.doi.org/10.1006/bbrc.1998.8159. (Pubitemid 28419934)
24. Ruhr E, Sahl HG. 1985. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 27:841-845. http://dx.doi.org/10.1128/AAC.27.5.841. (Pubitemid 15122003)
25. Koo SP, Bayer AS, Yeaman MR. 2001. Diversity in antistaphylococcal mechanisms among membrane-targeting antimicrobial peptides. Infect. Immun. 69:4916-4922. http://dx.doi.org/10.1128/IAI.69.8.4916-4922.2001. (Pubitemid 32674473)
26. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. http://dx.doi.org/10. 1038/nrmicro1098. (Pubitemid 40298223)
27. Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244:253-257. http://dx.doi.org/10.1006/bbrc.1998.8159. (Pubitemid 28419934)
28. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317. http://dx.doi.org/10.7326/0003-4819-144-5-200603070- 00005. (Pubitemid 46768185)
29. Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, Jansen A, Nielsen AK, Mygind PH, Raventós DS, Neve S, Ravn B, Bonvin AMJJ, De Maria L, Andersen AS, Gammelgaard LK, Sahl H-G, Kristensen H-H. 2010. Plectasin, a fungal defensin, targets the bacterial cell wall precursor lipid II. Science 328:1168-1172. http://dx.doi.org/10.1126/science.1185723.
30. Yeung AT, Gellatly SL, Hancock RE. 2011. Multifunctional cationic host defence peptides and their clinical applications. Cell. Mol. Life Sci. 68: 2161-2176. http://dx.doi.org/10.1007/s00018-011-0710-x.
31. Kumar JK. 2008. Lysostaphin: an antistaphylococcal agent. Appl. Microbiol. Biotechnol. 80:555-561. http://dx.doi.org/10.1007/s00253-008-1579-y.
32. Mah TF, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9:34-39. http://dx.doi.org/10.1016/ S0966-842X(00)01913-2.
33. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. 2011. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 9:62-75. http://dx.doi.org/10.1038/nrmicro2474.
34. Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55:27-55. http://dx.doi.org/10.1124/pr.55.1.2. (Pubitemid 36268398)
35. Lipsky BA, Holroyd KJ, Zasloff M. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47:1537-1545. http://dx.doi.org/10.1086/593185.
36. Dang CN, Prasad YD, Boulton AJ, Jude EB. 2003. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet. Med. 20:159-161. http://dx.doi.org/10.1046/j.1464-5491.2003.00860.x. (Pubitemid 36269659)
37. Lipsky BA, Stoutenburgh U. 2005. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55:240-245. http://dx.doi.org/10.1093/jac/dkh531. (Pubitemid 40331152)
38. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. 1999. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet. Med. 16:767-771. http://dx.doi.org/10.1046/j.1464-5491. 1999.00132.x. (Pubitemid 29459276)
39. Fejfarova V, Jirkovska A, Skibova J, Petkov V. 2002. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. Vnitr. Lek. 48:302-306. (In Czech.)
40. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E, Infectious Diseases Society of America. 2012. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 54:e132- e173. http://dx.doi.org/10.1093/cid/ cis346.
41. Sotto A, Lina G, Richard JL, Combescure C, Bourg G, Vidal L, Jourdan N, Etienne J, Lavigne JP. 2008. Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers: a new paradigm. Diabet. Care 31:2318-2324. http://dx.doi.org/10.2337/dc08-1010.
42. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS. 2013. Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One 8:e69508. http://dx.doi.org/10.1371/journal.pone.0069508.
43. Pirofski LA, Casadevall A. 2008. The damage-response framework of microbial pathogenesis and infectious diseases. Adv. Exp. Med. Biol. 635: 135-146. http://dx.doi.org/10.1007/978-0-387-09550-9-11.
44. Casadevall A, Pirofski LA. 2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1:17-24. http://dx.doi.org/10.1038/ nrmicro732.